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Parkinson’s disease (PD) is a common, disabling, neurodegenerative disorder. In addition
to classical motor symptoms, non-motor features are now widely accepted as part of the
clinical picture, and cognitive decline is a very important aspect of the disease, as it brings
an additional signiﬁcant burden for the patient and caregivers. The diagnosis of cognitive
decline in PD, namely mild cognitive impairment (MCI) and dementia, can be extremely
challenging, remaining largely based on clinical and cognitive assessments. Diagnostic cri-
teria and methods for PD dementia and MCI have been recently issued by expert work
groups. This manuscript has synthesized relevant data in order to obtain a pragmatic and
updated review regarding cognitive decline in PD, from milder stages to dementia. This
text will summarize clinical features, diagnostic methodology, and therapeutic issues of
clinical decline in PD. Relevant clinical genetic issues, including recent advances, will also
be approached.
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INTRODUCTION
Parkinson’s disease (PD) is the secondmost commonneurodegen-
erative disorder, following Alzheimer’s disease. Nearly 200 years
have gone by since James Parkinson’s original clinical depictions in
his monograph entitled An Essay on the Shaking Palsy (Parkinson,
1817; Goetz, 2011). The text focused mainly on the motor fea-
tures of PD, overlooking non-motor symptoms, with the notable
exception of “melancholy” – but cognitive impairment was at that
time completely disregarded. It is currently recognized that the
spectrum of non-motor features in PD is broad (Chaudhuri and
Schapira, 2009; Tolosa et al., 2009; Massano and Bhatia, 2012),
but these may often be missed in clinical practice. Nonetheless,
whenever PD is suspected, the routine approach should include a
set of questions aimed at exploring their presence, since they may
be helpful hints for the diagnosis, although they are non-speciﬁc
in this regard. On the other hand, it is useful to quantify their
severity and impact, as they carry an important additional bur-
den on the patients, leading to signiﬁcantly deteriorated quality
of life (QOL), and warranting speciﬁc therapeutic interventions,
despite the fact that evidence-based data on treatment are unsatis-
factory in many instances (Chaudhuri and Schapira, 2009; Tolosa
et al., 2009; Zesiewicz et al., 2010). Braak and coworkers have
greatly contributed to the awareness of the association between
symptoms and the neuropathological lesions affecting the ner-
vous system (Braak et al., 2003; Hawkes et al., 2010). Indeed, due
to long term progression and the mode of pathological spreading,
some of the non-motor features of PD may be present before any
of the classical motor signs are noticeable, sometimes for years
or even decades, which may lend them potential utility as sup-
portive diagnostic features in early disease stages – these include
hyposmia, rapid eye movement (REM) sleep behavior disorder,
constipation, and depression (Chaudhuri and Schapira, 2009; Lim
et al., 2009; Tolosa et al., 2009; Hawkes et al., 2010; Savica et al.,
2010; Schapira and Tolosa, 2010). Patients may have these and
other symptoms before overt motor signs emerge and the clinical
diagnosis is ﬁnally established. On the other hand, features like
dementia and hallucinations tend to occur later in the course of
disease, which might be useful for distinguishing PD from other
disorders. Cognitive impairment is a major non-motor feature
of PD, but the diagnosis is often complex, remaining based on
clinical skills and methods, as no reliable diagnostic biomarkers
have been described yet. Mild cognitive dysfunction is apparent
in many cases from early stages (Aarsland et al., 2009; Barone
et al., 2011; Domellöf et al., 2011; Litvan et al., 2011), but recent
research has shown that manifest dementia will occur in over 80%
of patients after 20 years of disease (Hely et al., 2008). Accurate
cognitive assessment and classiﬁcation is also paramount in the
context of deep brain stimulation for PD, an issue approached in
detail in the article by Massano and Garrett (2012), also part of
this Frontiers Research Topic. The present manuscript will cover
the clinical aspects of cognitive decline in PD, namely mild cogni-
tive impairment (MCI), and dementia (PD-D), including typical
features, diagnosis, and management issues.
METHODS
A comprehensive PubMed literature search was conducted for
papers published until September 2011, using the keywords
“Parkinson’s disease,” “Parkinson’s disease dementia,” “mild cog-
nitive impairment.” From all the references found, the authors
have consensually chosen those most relevant to the review, in
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order to obtain a clinically oriented perspective of the state of the
art knowledge regarding cognitive decline in PD. Exceptionally,
later references of interest, published in the meantime, have also
been considered.
EPIDEMIOLOGY OF PARKINSON’S DISEASE DEMENTIA
Due to differences in diagnostic criteria, methodology, and study
populations, epidemiological numbers regarding PD-D tend to
vary greatly. The prevalence of dementia in community-based
studies has been estimated at 30–40% (Aarsland et al., 2005; Aars-
land and Kurz, 2010) but ﬁgures range from about 10 to 80% of
people with PD (Aarsland et al., 2005; Aarsland and Kurz, 2010).
Even in young onset PD, deﬁned as symptoms emerging from
21 to 40 years (Schrag and Schott, 2006), dementia affects up to
19% of patients after a median of 18 years of disease duration
(Schrag et al., 1998). In addition, cognitive decline is noted in up
to 36% of newly diagnosed cases of PD (Reid et al., 1989; Foltynie
et al., 2004). From the published literature, it seems clear that the
prevalence of dementia increases with age and duration of the dis-
ease symptoms (Hughes et al., 2000; Aarsland and Kurz, 2010),
although some have suggested that patient age could be prepon-
derant (Aarsland et al., 2007). The Sydney Multicenter Study has
been an exceptional initiative in this ﬁeld of research, as one group
of clinicians followed a single cohort of newly diagnosed people
with PD over 20 years. Sydney neurologists were asked to refer
their newly diagnosed PD patients for a 5-year trial comparing
low dose bromocriptine with low dose levodopa/carbidopa (Hely
et al., 1994). During this study, neuropsychological assessments
were performed at baseline and at 3, 5, 10, and 20 years. At base-
line, 26 newly diagnosed PD patients were demented – by current
deﬁnitions, these would be classiﬁed as dementia with Lewy bod-
ies (DLB) cases. A neuropsychological diagnosis of dementia was
made on the basis of impairment inmemory and at least two other
areas of cognitive functioning. A test score at least two standard
deviations (SD) below the mean score obtained by the control
group was classiﬁed as cognitive impairment. The control group
consisted of 50 age-, gender-, and education-matched commu-
nity living people without PD, who were friends or relatives of the
patients. If no neuropsychological assessment was carried out, a
diagnosis of dementia was based on a Clinical Dementia Rating
score of at least 1, with supporting evidence of gradual cognitive
decline sufﬁcient to impair daily functioning. This was sustained
by performance in Mini-Mental State Examination (MMSE), let-
ter and category ﬂuency, and clock face drawing. At 20 years, 25 of
30 (83%) surviving patients had become demented and 2 others
have developed dementia subsequently (Hely et al., 2008).
In an earlier review of 27 studies, Cummings found a mean
prevalence of dementia in PD of 40%, even though at that
time studies did not include the identiﬁcation and exclusion of
patients with DLB (Cummings, 1988). The incidence of dementia
is increased by 2.8- to 6-fold in those with PD when compared
to those without the disease (Aarsland et al., 2005; de Lau et al.,
2005; Aarsland and Kurz, 2010). The cumulative prevalence is very
high – at least 75% of the patients with PD who survive for more
than 10 years will develop dementia (Aarsland and Kurz, 2010).
Several risk factors for PD-D have been proposed, includ-
ing certain predominant motor features such as rigidity and gait
instability, MCI, and the presence of visual hallucinations (Goetz
et al., 2008). Older age is broadly accepted as a risk factor for
dementia in PD. Some authors have found parameters such as
disease duration, age of onset, and motor symptom severity to
be signiﬁcant risk factors, but published data are at times contra-
dictory (Aarsland and Kurz, 2010). Interesting ﬁndings have been
brought to light regarding genetics and cognitive decline in PD, a
few of them quite recently, as we will further detail in the text.
PARKINSON’S DISEASE DEMENTIA: CLINICAL FEATURES
Dementia associated with PD holds suggestive phenotypic cogni-
tive features that make it a recognizable and individualized entity.
This issue will be further detailed, focusing on its mode of onset,
proﬁle of cognitive deﬁcits, behavioral aspects, and motor pheno-
type, as well as other features. Dementia adds substantially to the
burden of disease for the patient, caregiver, and the community
(Aarsland et al., 1999, 2000), thus warranting accurate diagnosis
and management.
PATTERN OF ONSET AND PROGRESSION
The onset of PD-D is insidious, often making it difﬁcult for the
patient and the family to evoke when the ﬁrst signs of cognitive
dysfunction started. The evolution is progressive. In one prospec-
tive, 4-year study, the mean annual MMSE decline was 1 point
in PD subjects without dementia versus 2.3 points in the PD-D
group, a ﬁgure similar to that seen in patients with AD (Aarsland
et al., 2004). During the 5 year follow-up of theCamPaIGN cohort,
researchers have found that MMSE scores declined at a mean rate
of −0.3± 0.1 points per year over the 5.2 years of average observa-
tion (Williams-Gray et al., 2009). Dementia in the early stages of
PD is not considered a typical feature of the disease (Massano and
Bhatia, 2012); by current consensus deﬁnitions, whenever parkin-
sonism and dementia arise in close temporal relationship, those
cases should be classiﬁed asDLB, as the diagnosis of PD-D requires
the preceding diagnosis of PD followed by the later development of
dementia (McKeith et al., 2005;Emre et al., 2007a). Early indicators
associated with cognitive decline may include excessive daytime
sleepiness (Gjerstad et al., 2002). Visual hallucinations are rela-
tively frequent, as are bizarre but ill-deﬁned misperceptions or
psychotic phenomena (such as feeling that there is someone else
in the room, when indeed this is not the case). Increasing apa-
thy, impaired attention and concentration, and forgetfulness are
also frequent features (Goetz et al., 2008), although memory com-
plaints as initial presentation are less frequent than in DLB and,
particularly, AD (Noe et al., 2004). The course of decline in PD-D
is relentless and progressive over time. Patients may remain sta-
ble for several months, at times with periods of faster worsening
with no additional obvious cause (Emre, 2010). Fluctuations occur
fromday to day and during the same day,which is a similar pattern
to that of DLB (Ballard et al., 2002).
Hobson and coworkers have studied a community based cohort
of PD patients with and without dementia. They found that
standardized mortality ratios (SMR) were signiﬁcantly higher in
PD-D patients than in PD non-demented individuals (SMR 3.10,
versus 1.15, p< 0.001). Life expectancy in younger-onset PD-D
(55–74 years old) was signiﬁcantly lower than in non-demented
patients (average 7.5 versus 12.4 years), and the estimated age
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at death was also much lower in the ﬁrst group (72.4 versus
77.8 years). Differences regarding life expectancy and age at death
in older-onset PD-Dwere less obvious (Hobson et al., 2010).Other
authors have also found an increased mortality risk among PD
patients with dementia (Levy et al., 2002; de Lau et al., 2005).
COGNITIVE PHENOTYPE OF PARKINSON’S DISEASE DEMENTIA
Assessment of cognition in PD patients can be a demanding
and exhausting mission for both the patient and examiner. Dis-
ease symptoms such as tremor, bradykinesia, bradyphrenia, pain,
fatigue, sleepiness, and mood disorders, as well as medication
effects, can interfere with cognitive performance and testing. Also,
timed tests can be seriously affected due to motor slowing, and
those depending on motor capacity to perform the task, such as
drawing, can be interfered by tremor.
Executive functions have been deﬁned as capacities that“enable
aperson to engage successfully in independent,purposive,and self-
serving behavior,”and encompass cognitive processes such as initi-
ation,planning,purposive action, self-monitoring, self-regulation,
volition, inhibition, and ﬂexibility (Stuss, 2011). Executive dys-
function has been widely recognized as a very important feature
of the cognitive phenotype of PD, even in non-demented patients,
althoughpublisheddata has beenmarredby inconsistencies in def-
initions and research methods (Kudlicka et al., 2011). The most
widely used tests to probe executive functioning in PD have been
verbal ﬂuency, digit span backward, Wisconsin Card Sorting Test,
Stroop Test, and Trail Making Test (Kudlicka et al., 2011). Accu-
mulated research data has shown that executive dysfunction is a
prominent feature in PD-D (Tröster, 2008; Kehagia et al., 2010).
There is clinical and electrophysiological evidence of slowed
cognition in PD-D, although this may be apparent even in non-
dementia stages (Rogers et al., 1987; Owen et al., 1992; O’Mahony
et al., 1993; Hanes et al., 1996; Turner et al., 2002). Attentional
deﬁcits have been consistently shown in PD-D. In tests such as the
letter cancelation test and others, PD-D patients are slower, tend
to ﬂuctuate more, and incur on a higher number of errors than
AD subjects, whereas the proﬁle of PD-D seems to be similar to
that seen in DLB (Ballard et al., 2002; Noe et al., 2004; Bronnick
et al., 2007).
Visuospatial function is a term used to describe a wide range of
functions that must be assessed by different tests, the unifying fea-
ture being that all of them rely on visual function and processing
(Jeannerod and Jacob, 2005). Findings from studies pertaining to
this matter have shown greater deﬁcits in PD-D than AD patients
(Starkstein et al., 1996). It has been shown that visual percep-
tion, space-motion, and object-form perception are globally more
impaired in PD-D patients than in control subjects, including nor-
mal controls and non-demented PD patients, and AD (Mosimann
et al., 2004).
In PD-D, short term memory is impaired, both for initial
learning and immediate recall. Traditionally, mnesic deﬁcits in
PD have been considered to be mainly of retrieval, rather than
encoding and storage (Pillon et al., 1993). In PD-D, however,
patients may also be impaired on cued recall (Higginson et al.,
2005). A large meta-analysis has shown that verbal ﬂuency impair-
ment is more pronounced than that seen in PD non-demented
patients; also, semantic ﬂuency seems to be more compromised
than phonemic ﬂuency (Henry and Crawford, 2004). Concept
formation is also impaired in PD-D (Cahn-Weiner et al., 2002,
2003). The Clock-Drawing Test displays marked changes in PD-D,
although it is similar to that found in DLB, and AD. PD-D and
DLB patients demonstrate more planning errors, as compared to
AD (Cahn-Weiner et al., 2003).
Signiﬁcant dysphasia is not typically seen in PD-D, and lan-
guage deﬁcits occur much less frequently in PD-D than in AD
(Pillon et al., 1993; Frank et al., 1996; Kramer and Duffy, 1996).
Certain phenotypic characteristics pertaining to cognitive
decline have been used to differentiate “cortical” from “subcorti-
cal” dementia syndromes (Darvesh and Freedman, 1996; Salmon
and Filoteo, 2007; Bonelli and Cummings, 2008). Cortical demen-
tia syndromes display impairments of cognitive domains such as
episodic memory, praxis, language, and calculation, whereas sub-
cortical dementias tend to show slowed mental processing speed
and frontal lobe changes such as apathy, irritability, and dysexec-
utive impairment. The “cortical” proﬁle is typical of AD, whereas
PD-D and DLB typify the “subcortical” dementia type, but many
cases ﬁt the opposite prototype (Janvin et al., 2006). Character-
istically, early impairment of episodic memory is seen in AD, in
accordance to thepathological changes seen in this disorder (Wein-
traub et al., 2012). For more details on the clinical features of AD
please refer to the manuscript by Alves et al. (2012) included in
this Frontiers Research Topic.
BEHAVIORAL OR NEUROPSYCHIATRIC SYMPTOMS
Psychotic symptoms
Hallucinations occur in 45–65% of PD-D patients, a higher rate
than in the general population of PD; these come about usually in
the visual perceptual modality (Aarsland et al., 2001a,b,c). In PD
patients without dementia, hallucinations are an important pre-
dictor for the development of dementia and institutionalization
(Giladin et al., 2000). Hallucinations tend to be more common
in DLB than in PD-D and in these more frequent than in AD
(Hirono et al., 1999; Aarsland et al., 2000, 2001a,b; Benoit et al.,
2005). Hallucinations in PD-D and DLB tend to present similar
characteristics, as they are usually complex and well formed, often
colorful moving images, with people and animals being a frequent
motif (Williams and Lees, 2005; Janvin et al., 2006). Brief, ill-
deﬁned peripheral images (de passage) may also occur and be less
appreciated by the patient (Fenelon et al., 2000). Delusions seem
to be less frequent than hallucinations in PD-D, and are estimated
to occur in about 30% of patients; this rate is greater than in AD
but lower than in DLB (Aarsland et al., 2001b). Delusional activ-
ity in PD-D includes “feeling of presence,” phantom boarder (the
delusional belief that there are foreign people in the house, who
may even interfere with the patient’s life, e.g., eat their food or mis-
place their objects), paranoid, or grandiose delusions; delusional
activity may be broad or isolated to a single subject.
Mood and anxiety
Aarsland and coworkers have conducted a community-based study
and have documented major depression in 13% of PD-D sub-
jects, compared with 9% of non-demented PD patients. This rate
is lower than in DLB, but greater than in AD (Starkstein et al.,
1996; Aarsland et al., 2001a). Dysphoric mood with depressive
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symptoms occurs with approximately the same frequency in PD-D
andAD (40–58%) patients (Aarsland et al., 2001b). Anxiety occurs
at a similar frequency (30–49%) as depressed mood, and these
symptoms may frequently co-exist in the same patient (Menza
et al., 1993; Bronnick et al., 2005). Irritable mood, anger, and
aggression are common in AD, but uncommon in PD-D (Engel-
borghs et al., 2005). Manic or hypomanic mood is infrequently
seen in PD-D (Starkstein et al., 1996).
Apathy
It has been reported in 54% of patients in a large sample of mild to
moderate PD-D (Aarsland et al., 2001b). Prominent apathy is very
common in other forms of dementia, including frontotemporal
dementia (Kertesz, 2003), progressive supranuclear palsy (Aars-
land et al., 2001c),AD (Benoit et al., 2005), and DLB (Engelborghs
et al., 2005); thus, this feature is not speciﬁc enough to guide
diagnosis.
NON-COGNITIVE FEATURES OF PARKINSON’S DISEASE
DEMENTIA
Non-motor complications of PD-D are frequent, and those fea-
tures are now assumed to be an intrinsic part of the pathological
processes involved. Therefore, it seems legitimate to assume that
motor and non-motor features must be interrelated. PD-D neu-
ropathological ﬁndings are detailed in the manuscript by Taipa
et al. (2012), included in this Frontiers Research Topic.
MOTOR PHENOTYPE
There is the notion that certain motor features, such as postural
instability and gait disorder (PIGD) are associated with a faster
progression rate of cognitive decline in PD, being a risk factor
for dementia (Burn et al., 2006). Levy et al. (2002) have docu-
mented that older patients with more severe parkinsonian signs
had a relatively increased risk for incident dementia than younger
and mildly affected subjects. Tremor predominance as the initial
presentation has been associated with a lower risk for cognitive
decline in some studies. These patients seem to remain protected
against cognitive decline, unless they evolve to the PIGD pheno-
type (Elizan et al., 1986; Reid et al., 1989; Wood et al., 2002).
Clinicopathological studies have shown that dementia is most
common in PD patients with akinesia/rigidity than in the tremor
dominant and mixed phenotypes (Rajput et al., 2009; Selikhova
et al., 2009). Poorer cognitive performance is also associated with
poorer outcomes in motor and non-motor domains, as a study
by Papapetropoulos et al. (2004) has shown. PD-D also seems to
be an independent risk factor for falls; other predictors of cogni-
tive decline include previous falls, longer time from disease onset,
and decreased arm swing (Wood et al., 2002; Pickering et al.,
2007). For levodopa responsivity, data are inconsistent in showing
any pattern that differentiates PD-D patients from PD patients
without dementia (Stern et al., 1993; Bonelli et al., 2004). A 3-
year longitudinal study, however, documented greater cognitive
decline in PD patients with less than a 50% levodopa-induced
improvement at baseline (Caparros-Lefebvre et al., 1995). Fur-
thermore, an autopsy study has suggested that loss of levodopa
responsivity is correlated with dementia due to greater loss of
striatal D3 receptors (Joyce et al., 2002). Although fewer dyskine-
sias were reported in PD-D patients in a cross-sectional study, a
longitudinal study found greater mental deterioration in those PD
patients with baseline levodopa-induced dyskinesias (Elizan et al.,
1986; Caparros-Lefebvre et al., 1995).
SLEEP DISORDERS
REM sleep behavior disorder (RBD) is characterized by dream
enacting behavior, such as jumping out of bed, talking, or kick-
ing. While in REM sleep, abnormal electromyographic activity
is present, thus demonstrating the anomalous absence of muscle
atonia during this stage of sleep (Olson et al., 2000; Iranzo et al.,
2006; Frauscher et al., 2008). The pathophysiology is thought to
be related to lesions inﬂicted on the brainstem REM sleep centers
that inhibit the spinal cord motoneurons and their connections,
as these structures are usually damaged in PD (Boeve et al., 2009;
Iranzo, 2011).
REM sleep behavior disorder may be idiopathic or linked to
several neurodegenerative diseases such as PD, DLB, and multiple
system atrophy. A study by Iranzo and collaborators has reported
that 45% of the idiopathic RBD patients studied developed a neu-
rological disorder after a mean of 11.5 years from the reported
onset of RBD – PD in nine patients (two of them with dementia),
DLB in six, MSA in one, and MCI in four by the end of the 5 year
follow-up period. Neuropsychological evaluation disclosed cogni-
tive decline of various degrees of severity; three of the four MCI
patients showed visuospatial deﬁcits and short term free recall
impairment that beneﬁted from external cues (Iranzo et al., 2006).
Patients with idiopathic RBD usually do not report cognitive
problems, but Terzaghi et al. (2008) demonstrated that a visuospa-
tial constructiondeﬁcitwas present in 44%of the patientswho suf-
fered from idiopathic RBD. The cognitive proﬁle found in patients
with idiopathic RBD usually comprises visuospatial capacities,
verbal memory, attention, and executive function impairment.
Usually these subjects show no impairment in semantic mem-
ory and language, deﬁcits commonly seen in AD (Ferrini-Strambi
et al., 2004; Weintraub et al., 2012). Similarities have also been
found between EEG patterns of idiopathic RBD,with cortical EEG
slowing (abundant delta and theta waves) in frontal, temporal, and
occipital regions, also found in PD and DLB patients (Kai et al.,
2005; Caviness et al., 2007b). Some studies have tried to charac-
terize RBD patients with MCI. Gagnon and coworkers have found
that most PD patients (73%) with RBD display MCI, while many
patients with idiopathic RBD (50%) also show MCI. The main
subtypes of MCI seem to be single domain non-amnestic and
amnestic in PD,while in idiopathic RBD the predominant subtype
was non-amnesticMCI; all these patients displayed predominantly
executive-attentional impairment (Gagnon et al., 2009). It is cur-
rently accepted that RBD occurs in PD patients with associated
MCI and dementia, however RBD may also occur in PD patients
with no associated cognitive deﬁcits (Iranzo et al., 2005; Gagnon
et al., 2009).
AUTONOMIC SYMPTOMS
Dementia and signiﬁcant autonomic features may develop in the
course of PD, especially in later stages (Hely et al., 2005; Hawkes
et al., 2010), hence one could presumably postulate an association
between autonomic symptoms and PD-D. This is however yet to
be proven by comprehensive studies. The amount of data on the
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relative frequency of autonomic features in demented compared
to non-demented PD patients is scarce. Idiaquez and collabora-
tors have assessed 40 PD patients and 30 age matched controls
for cognitive and behavioral manifestations using standardized
neuropsychological tools. These subjects were assessed for ortho-
static hypotension, heart rate, and responses to deep breathing
(SCOPA-AUT): 11 of these patients fulﬁlled the DSM-IV criteria
for dementia and a higher incidence of cardiovascular dysfunction
were found amongst demented patients (Idiaquez et al., 2007).
The presence of autonomic dysfunction has also been reported in
the Sydney multicenter study, after 15 years follow-up. Orthosta-
tic hypotension was found in 35% and urinary hypotension has
also been reported in 41% of PD patients and these were most fre-
quent among those with higherHohen andYahr scores (Hely et al.,
2005). In this study, however, it was not speciﬁed whether or not
autonomic symptoms were more frequent in demented patients.
The pathophysiologicalmechanisms of autonomic dysfunction
seem to be related to typical synuclein deposits throughout the
central and peripheral autonomic nervous systems. The extension
of these deposits to the limbic and cortical areas may be the cause
for the associated development of dementia. Trying to deﬁne the
neural substrate of autonomic dysfunction is difﬁcult, as both sys-
tems may be implicated. Comorbidities are also important, as the
presence of symptoms, such as orthostatic hypotension, constipa-
tion, and urinary incontinence may be due to other causes besides
autonomic dysfunction. For instance, dopaminergic drugs may
also cause dysautonomic symptoms, leading to constipation, and
urinary incontinence (Winge and Fowler, 2006; Allan et al., 2007).
In summary, PD-D patients typically present with dysexecutive
syndrome, ﬂuctuating attentional deﬁcits, visuospatial impair-
ment, and memory dysfunction, associated with behavioral symp-
toms (Emre et al., 2007a), which include depression, anxiety,
apathy, delusions, and recurrent prominent complex visual hal-
lucinations that may seem disproportionate to the severity of
dementia. PD-D is most frequently associated with the postural
imbalance gait disability motor phenotype of PD. The evolution
is progressive. These clinical features are in many aspects similar
to those seen in DLB, and distinguishing both disorders from each
other can be challenging (McKeith, 2005;Metzler-Baddeley, 2007).
DIAGNOSTIC CRITERIA FOR PARKINSON’S DISEASE
DEMENTIA
For a long time, speciﬁc diagnostic criteria did not exist for PD-D.
Clinicians and researchers had to formally support this diagno-
sis with the help of generic criteria for dementia, such as those
set by the Diagnostic and Statistical Manual of Mental Disor-
ders fourth edition (DSM-IV; American Psychiatric Association,
1994). Finally, criteria aimed speciﬁcally at the diagnosis of PD-D
have been published in 2007, proposed by a Movement Disorder
Society task force. Two levels of clinical diagnostic certainty have
been deﬁned: possible and probable PD-D (Emre et al., 2007a).
According to this document, the essential deﬁning feature of PD-
D is the emergence of dementia in the setting of established PD,
as diagnosed according to the Queen Square Brain Bank criteria.
Dementia is deﬁned as a syndrome of insidious onset and progres-
sive decline of cognition and functional capacity fromapremorbid
level, that is not attributable to motor or autonomic symptoms.
Impairment in at least two of the four typically involved cog-
nitive domains (impaired and often ﬂuctuating attention; dysex-
ecutive changes; impaired visuospatial abilities; and impaired free
recall that improves with cueing) must be documented without
prominent language dysfunction, as demonstrated by clinical and
cognitive examination. The authors take into account that the
main behavioral or neuropsychiatric symptoms seen in PD-D
include visual hallucinations, delusions, apathy, depressed mood,
anxiety, and excessive daytime sleepiness. These features are fre-
quent in PD-D, but their presence is not invariable. The presence
of at least one symptom from this set supports, but is not required
for, the diagnosis of PD-D. Further details on diagnostic criteria
for PD-D can be found in Emre et al. (2007a) and the proposed
neuropsychological assessment methods to be carried out with
these patients have been published in Dubois et al. (2007), from
the same workgroup.
Clinical validation efforts have been carried out from experi-
enced groups in this ﬁeld, regarding this proposal. Dujardin and
coworkers have enrolled 188 PDpatients,which have been assessed
using the two-step cognitive evaluation recommended by theMDS
task force (shorter battery followed by longer comprehensive cog-
nitive assessment battery), recording also the presence or absence
of dementia after each step had been taken. After the short battery
had been applied 18.62% of PD patients were suspected of having
dementia, whereas 21.81% fulﬁlled criteria for probable PD-D
following the longer battery. The authors have found that the
short battery’s sensitivity and speciﬁcity were 65.85 and 94.56%,
respectively – but using speciﬁc cutoff scores the sensitivity would
increase considerably without signiﬁcant loss of speciﬁcity, thus
suggesting that PD-D can be diagnosed accurately with the shorter
battery as well as the longer assessment method. Speciﬁcally, an
MMSE score <27, the inability to recall ﬁve words immediately
after learning, being unable to generate>7 words beginning with
“S” within 60 s, the lack of full personal independence in manag-
ing antiparkinsonian medications, and age >69 years seem to be
associated with a high probability of PD-D (Dujardin et al., 2010).
Martinez-Martin and coworkers have compared the MDS cri-
teria for the diagnosis of PD-D with dementia criteria established
by the DSM-IV. In this study, 299 PD patients have been enrolled,
and the authors have found out that the DSM-IV criteria failed to
identify 22% of patients fulﬁlling the MDS criteria. False negative
cases were older and had more severe motor symptoms, but less
psychosis than those true non-demented PD. False positives had
less severe motor symptoms than true PD-D, although the differ-
ence did not reach statistical signiﬁcance. These ﬁndings suggest
that the MDS criteria are more sensitive than DSM-IV for diag-
nosing PD-D, and that it could be more difﬁcult to diagnose PD-D
in older patients, as well as those with less psychotic symptoms or
severe motor impairment (Martinez-Martin et al., 2011).
Another clinical study aimed at comparing the diagnostic
acuity for PD-D of the eight-item screening checklist proposed
by the MDS task force, as compared to full neuropsychologi-
cal assessment. This is an important issue since comprehensive
neuropsychological testing is not widely available in every practice
setting, thus short screening tools would be most welcome. The
authors have assessed 91 PD patients – of these 7 (7.7% of all
subjects) met criteria for probable PD-D based on the screening
www.frontiersin.org May 2012 | Volume 3 | Article 88 | 5
Meireles and Massano Cognitive impairment and dementia in Parkinson’s disease
checklist, whereas 15 patients (16.5%) were detected using full
neuropsychological testing; of note, all patients that met criteria
for PD-D according to the screening checklist also did with longer
neuropsychological testing (100% speciﬁcity). These results imply
that the screening checklist performed at 46% sensitivity for the
diagnosis of PD-D, although agreement was moderate between
both methods (κ 0.59, p< 0.001). The most common reasons for
false negative misclassiﬁcation by the screening checklist were that
subjects were not deemed to be free of depression (5 patients),
they had an MMSE score of at least 26 (6 patients), and they were
not rated as impaired in activities of daily living (1 patient). Alto-
gether, these results suggest that the screening checklist proposed
by the MDS task force for the diagnosis of PD-D is speciﬁc when
all eight items are met, but sensitivity is low, thus a signiﬁcant
number of false negative cases are to be expected. Therefore, this
does not seem to be an ideal screening instrument. The authors
have also demonstrated that the sensitivity of this tool could be
largely increased if two problem items would be removed (absence
of depression, abnormal MMSE score), something that should be
considered in future research (Barton et al., 2012).
Ideally, clinicopathological validation studies should also be
carried out in the future using the MDS criteria for the diagno-
sis of PD-D, in order to promote in-depth understanding of their
diagnostic acuity. Hopefully, the proposal from theMDS task force
will at least bring uniform deﬁnitions and methods into clinical
care and research in the setting of PD-D.
MILD COGNITIVE IMPAIRMENT IN PD
In a way somewhat analogous to what can be perceived in the
course of Alzheimer’s disease, a pre-dementia period exists in PD
(see Figure 1). In a wide-ranging manner, MCI can be deﬁned as
a cognitive decline from a previous performance baseline, that is
considered abnormal for the patient’s age, but with retention of
normal daily functioning. Such a condition appears to be quite
frequent in PD, even in early stages and also prior to the initiation
of dopaminergic therapy (Muslimovic et al., 2005; Caviness et al.,
2007a; Domellöf et al., 2011; Litvan et al., 2011). In clinical and
research settings, the term is applied to PD patients who present
cognitive complains and whose neuropsychological examinations
conﬁrm thedeﬁcits,but PD-Dcriteria cannot be fulﬁlleddue to the
lack of overt functional decline related to cognitive impairment.
Deterioration can occur in a range of cognitive domains. How-
ever, non-amnestic single domainMCI seems to bemore common
than amnestic single domain MCI (Pillon et al., 1993; Caviness
et al., 2007a; Litvan et al., 2011). Nonetheless, the predictive value
regarding the future risk of dementia of each of the MCI subtypes
has not been thoroughly assessed in prospective studies (Barone
et al., 2011).
From the published data, it is apparent that most PD patients
will develop dementia, provided that enough time elapses since
disease onset. Since PD-MCI precedes PD-D, one could postulate
that the lifelong cumulative prevalence of PD-MCImust be at least
as high as that of PD-D. Approximately 27% of PD patients will
meet criteria for PD-MCI at any given time (Litvan et al., 2011).
Aarsland et al. (2010) have reported that PD-MCI affects 25.8% of
PDpatients (ranging between 23.5 and 28.8%). There is signiﬁcant
variability among the numbers reported,whichmay be justiﬁed by
methodological differences, namely deﬁnitions used, the cognitive
domains assessed, how impairment was deﬁned for the test, and
the fact that different patient populations have been enrolled.
An interesting population based study using a sample of 239
newly diagnosed PD patients has found an incidence rate of cog-
nitive impairment of 36%. From this subgroup, 21% scored 1 or
more SD below the mean on a pattern recognition memory test,
being subsequently classiﬁed as having temporal lobe impairment.
Thirteen percent scored below the cut off score on a test evaluat-
ing frontostriatal deﬁcit, and 15% were impaired in both tests,
suggesting a more global impairment (Foltynie et al., 2004). A
second study used an extensive neuropsychological test battery to
compare the performance of a sample of 115 newly diagnosed PD-
D patients (mean disease duration of 19months) and 70 healthy
controls. Using a deﬁnition for impairment as <2 SD below the
normative sample mean score on at least 3 tests, PD patients per-
formed signiﬁcantly worse across most tests, and 24% of them
were deemed cognitively impaired. The patient group performed
worse in executive function,memory, complex attention, and psy-
chomotor speed tests (Muslimovic et al., 2005). Several studies
have found that increasing age, late disease onset, severity of PD,
and lower educational level are risk factors associated with PD-
MCI (Pai and Chan, 2001; Foltynie et al., 2004; Muslimovic et al.,
2005; Mamikonyan et al., 2009).
The complexity of deﬁning MCI in early stages of PD is high,
for signiﬁcant confusion with early DLB should be anticipated.
On the other hand, there is a concern that the deﬁnitions used
to determine MCI may lack sensitivity to detect early cogni-
tive decline in high functioning people, as these have to suffer
added decline before they reach the deﬁned cutoff below norma-
tive means. Hence they may potentially be classiﬁed cognitively
unimpaired when in fact a decline from baseline performance has
already occurred. It is commonly argued that high functioning
people may have additional protection from dementia – but their
work and social settings also tend to be more demanding, and
subtle cognitive decline may thus become more apparent. Impor-
tantly, the clinical deﬁnition of MCI requires that the person has
experienced a change in cognition, compared to baseline (Litvan
et al., 2011).
PROFILE OF COGNITIVE IMPAIRMENT
A number of studies assessing cognitive functioning in non-
demented PD have been published. Cognitive deﬁcits in PD are
traditionally seen as subcortical in their nature, as several stud-
ies have demonstrated that there is a signiﬁcant impairment in
executive functions such as poor planning, sequencing, cognitive
ﬂexibility, and problem solving capacities (Pai and Chan, 2001;
Muslimovic et al., 2005; Barone et al., 2011). Memory impair-
ments, including encoding, recall, and proceduralmemory are also
affected (Foltynie et al., 2004). Recognition is thought to remain
relatively well preserved (Foltynie et al., 2004). Language dysfunc-
tion is rarely reported, with an exception of deﬁcits in phonemic
and semantic tasks, which exist and tend to decline over time and
with disease severity, as evaluated by the Hoehn and Yahr stage,
predicting also a future diagnosis of dementia (Barone et al., 2011).
Identifying PD-MCI is clinically relevant, given that these
patients appear to be at increased risk for developing PD-D
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FIGURE 1 | schematic representation of the progression of PD patients
until the stage of dementia. Functional impairment in PD is multifactorial
(motor symptoms, cognitive decline, other non-motor symptoms). Please
note that this graph is merely pictorial; it is not intended to represent
proportions between variables nor is the progression linear, despite the
drawing.
(Litvan et al., 2011). On the other hand, one wonders if drug ther-
apy known to be effective in PD-D could be also of beneﬁt at the
stage of MCI, although this has not been formally studied in large
trials. A contributing factor for this might be the lack of broadly
accepted deﬁnitions and efﬁcacy endpoints. In this regard, a very
recent advance has been achieved, as the ﬁrst set of consensus
diagnostic criteria for PD-MCI have been proposed (Litvan et al.,
2012).
DIAGNOSTIC CRITERIA FOR MCI IN PARKINSON’S DISEASE
The clinical validity of PD-MCI has found strong support in the
published literature (Litvan et al., 2011). This concept has been for-
mally accepted and used for several years, but only very recently
has the ﬁrst set of criteria for the formal diagnosis of PD-MCI
been proposed (Litvan et al., 2012). A great contributor to a stag-
nant state regarding concrete deﬁnitions and criteria has been the
scarcity of long term in-depth prospective studies that would allow
better characterization of the phenotype of PD-MCI, to estab-
lish biomarker correlates, and to clearly deﬁne the progression
and risk of dementia for PD-MCI patients. The MDS task force
on PD-MCI has built this concept on the previous classic deﬁni-
tions of MCI and made the necessary adjustments regarding the
speciﬁcities of PD. The diagnosis of this condition requires a few
key points. First of all, the diagnosis of PD should be well estab-
lished. Then, cognitive decline must be reported by the patient
or caregiver, or documented by the clinician. These are subse-
quently documented by means of formal cognitive assessment.
Lastly, cognitive impairment must not cause signiﬁcant functional
decline. Exclusion criteria have also been described and two levels
of assessment and diagnostic certainty have been proposed (Lit-
van et al., 2012). The manuscript issued by this task force also
proposes speciﬁc assessment tests and scales, which will hopefully
expedite the homogenization and alliance of procedures through-
out practice and research settings all over the world. However, no
biomarkers could be recommended at this stage to incorporate the
diagnostic criteria, as evidence is still scarce concerning thismatter
in the ﬁeld of PD-D (Litvan et al., 2012).
GENETICS AND COGNITIVE DECLINE IN PD
HEREDITARY FORMS OF PARKINSON’S DISEASE AND COGNITION
Ten to 15% of PD patients disclose a family history suggesting
Mendelian inheritance, either autosomal dominant or recessive.
These tend to be younger than the typical PD patients (Schrag
and Schott, 2006; Tan and Jankovic, 2006). A number of lev-
odopa responsive parkinsonian syndromes have been described
and linked to a speciﬁc locus or gene, and 18 of these so far
have been classiﬁed as PARK syndromes (Klein and Westenberger,
2012). While some of these represent true PD, others denote more
complex phenotypes and different diseases (Gasser, 2007; Klein
et al., 2009), which we will not address in this manuscript.
Several autosomal dominant forms of PD have been described,
the most important being PARK1/PARK4 (gene SNCA, α-
synuclein) and PARK8 (gene LRRK2, leucine-rich repeat kinase 2).
In PARK1/PARK4, which are infrequent forms of PD, symptoms
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usually emerge in the fourth or ﬁfth decades, and patients dis-
play typical PD features, except that early prominent cognitive
decline and dementia is a common event. Hence, the clinical pic-
ture may resemble DLB, although age at onset is much lower than
in the classical cases. PARK1 and PARK4 are due to SNCA muta-
tions and duplications/triplications, respectively (Polymeropoulos
et al., 1997; Spira et al., 2001; Zarranz et al., 2004). PARK8 is prob-
ably the most common type of inherited PD. It has been reported
that mutation frequency is about 40% in North African Arabs and
Ashkenazi Jewish populations; high mutation frequency has also
been reported in populations from southern Europe (Healy et al.,
2008). The clinical picture resembles that of classical sporadic PD
(Wszolek et al., 2004;Healy et al., 2008), and cognitive singularities
have not been reported in this form of the disease,with a dementia
prevalence of about 11% (Kasten et al., 2010).
Three forms of autosomal recessive PD have been described:
PARK2 (gene Parkin), PARK6 (gene PINK1, PTEN-induced puta-
tive kinase 1), and PARK7 (gene DJ-1), here listed by decreasing
order of frequency. The clinical pattern of PARK2 includes, in
addition to typical PD features, a variety of symptoms such as
hyperreﬂexia, prominent dystonia, sensory axonal neuropathy,
increased sensitivity to levodopa induced dyskinesias, and psy-
chosis (Abbas et al., 1999; Klein et al., 2000; Lücking et al., 2000;
Gouider-Khouja et al., 2003; Khan et al., 2003; Deng et al., 2006;
Wickremaratchi et al., 2009). Notably, non-motor symptoms seem
to be less prevalent than in sporadic PD, except anxiety (Kägi et al.,
2010). Therefore, cognitive decline is apparently less frequent,
as compared to sporadic PD. Lewy bodies were absent in most
patients that came to autopsy (Farrer et al., 2001; Gouider-Khouja
et al., 2003). Age at onset of symptoms ranges from childhood
to mid-ﬁfties. It accounts for most PD cases under the age of
30 years. PARK6 and PARK7 share many common clinical fea-
tures with PARK2, including early onset, excellent response to
levodopa, and frequent levodopa induced dyskinesias, but psychi-
atric features may be more prominent in PARK6 (Valente et al.,
2001, 2002, 2004; van Duijn et al., 2001; Abou-Sleiman et al.,
2003; Dekker et al., 2003; Bonifati et al., 2005; Ibáñez et al., 2006;
Leutenegger et al., 2006; Steinlechner et al., 2007; Kasten et al.,
2010).
GLUCOCEREBROSIDASE MUTATIONS: MORE THAN A SIMPLE RISK
FACTOR FOR PD
Interesting observations have been made in the last few years in
families with members suffering from Gaucher’s disease, an auto-
somal recessive disorder caused by homozygous mutations in the
GBA gene encoding the lysosomal enzyme glucocerebrosidase.
Some years ago, heterozygous GBA mutations have been associ-
atedwith a higher risk of PD (Aharon-Peretz et al., 2004; Sidransky
et al., 2009), and data even suggested that these patients could have
an increased risk for cognitive impairment. For instance, Brock-
mann et al. (2011) have found that non-motor symptoms, among
them dementia, seem to be more prevalent in GBA-associated
PD than in mutation non-carriers. Two pathogenic mutations
(L444P and N470S) seem to be particularly prevalent, but oth-
ers have been described (DePaolo et al., 2009; Neumann et al.,
2009; Sidransky et al., 2009; Velayati et al., 2010). Interestingly,
GBA heterozygosity has also been associated with DLB, another
synucleinopathy that shares clinical and pathological features with
PD-D (Clark et al., 2009). Further clarifying these issues, Setó-
Salvia and coworkers have recently investigated GBA mutations in
DLB and PD-D,by fully sequencing the gene in 225 PDpatients, 17
pathologically proven DLB patients and 186 controls. Mutations
were signiﬁcantly more frequent in PD and DLB as compared to
controls, and PD patients carrying GBA mutations were at higher
risk of dementia, with an estimated adjusted odds ratio of 5.8,
p = 0.001 (Setó-Salvia et al., 2012). In fact, previous research has
shown that GBA mutations are associated with more diffuse Lewy
body neuropathology and greater neocortical involvement, which
might explain the higher risk of cognitive decline in these PD
patients (Neumann et al., 2009; Nishioka et al., 2011). Specula-
tion has been brought to light about the putative association of
other lysosomal disorders and parkinsonism (Shachar et al., 2011).
For further details on this topic please refer to the manuscript
by Almeida included in this Frontiers Research Topic (Almeida,
2012).
A word of caution should be given regarding GBA testing in
clinical practice. Current evidence clearly shows that heterozygous
pathogenic mutations are a risk factor for PD and DLB. Thus, it
has not been demonstrated that GBA mutations cause a mono-
genic form of PD or DLB. Therefore, similarly to what has been
suggested for ApoE genotyping in AD (Goldman et al., 2011),
testing for GBA mutations is not currently recommended with
clinical diagnostic purposes. Similarly, testing cannot be recom-
mended for the diagnosis of PD-D. Nonetheless, further scientiﬁc
research should be encouraged regarding GBA in PD, as many
aspects remain enigmatic.
MICROTUBULE ASSOCIATED PROTEIN TAU AND COGNITIVE DECLINE
IN PD
Traditionally, microtubule associated protein tau (MAPT) gene
mutations have been linked to autosomal dominant frontotempo-
ral dementia, usually the behavioral variant, in particular the clin-
ical forms also displaying parkinsonism (Galimberti and Scarpini,
2012). In addition, MAPT haplotype H1 has been associated with
increased susceptibility for the development of PD (Elbaz et al.,
2011; Trotta et al., 2012). In recent years, an interesting relation-
ship has been acknowledged between MAPT haplotype H1 and
clinical progression in PD, speciﬁcally with regard to cognitive
decline.Williams-Gray and coworkers have followed up their inci-
dent community PD CamPaIGN cohort and at 5 years (n = 162)
have found that 17% of patients had developed dementia. In this
study MAPT haplotype H1 was associated with accelerated cog-
nitive decline, and was also a signiﬁcant independent predictor of
dementia,alongwitholder age,andpoorperformanceon semantic
ﬂuency and pentagon copy at diagnosis. The authors have con-
ducted additional postmortem research using brain bank tissue,
demonstrating that the H1 haplotype was also associated with
20% more deposit load of 4 repeat tau in Brodmann area 46 in
Lewy body disease brains (PD or DLB), as compared to the H2
haplotype (Williams-Gray et al., 2009). The same working group
subsequently assessed a representative group of 132 PD patients
from this cohort for up to 7.9 years from diagnosis, and tau hap-
lotype H1 remained a strong risk factor for dementia at this time
point (Evans et al., 2011).
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In a Spanish case-control study MAPT haplotypes were deter-
mined in 202 PD patients (48 of these with dementia), 41 patients
with DLB (pathologically conﬁrmed in 17), 164 patients with AD,
and 374 controls. The authors have found that the haplotype H1 is
signiﬁcantly overrepresented in PD patients compared with con-
trols and that the association was signiﬁcantly stronger in PD-D
than in non-demented PD patients, suggesting that MAPT H1
haplotype seems to be a strong risk factor for PD and for dementia
in PDpatients. In addition, no association could be found between
any of theMAPT subhaplotypes andDLBorAD (Setó-Salvia et al.,
2011).
The groups led byAndrew Siderowf has studied genotypic vari-
ants of apolipoprotein E (APOE), catechol-O-mehyltransferase
(COMT ), and MAPT, and whether these could be correlated with
cognitive decline in PD in 212 clinically diagnosed patients fol-
lowed up prospectively. APOE allele E4 was associated with faster
decline, and MAPT and COMT could be correlated with perfor-
mance inmemory and attention, respectively, but not with the rate
of general cognitive decline, as assessed with the Mattis Dementia
Rating Scale version 2. Of note, 96% of patients in this cohort were
assessed no later than at 3 years of follow-up (Morley et al., 2012).
MANAGEMENT OF PD-D: GENERAL PRINCIPLES
Parkinson’s disease patients suffer signiﬁcant decline in their QOL,
due tomotor symptoms,motor complications inducedbyprogres-
sive neurodegeneration and medication effects, and non-motor
symptoms (Chaudhuri and Schapira, 2009; Lim et al., 2009; Tolosa
et al., 2009; Calabresi et al., 2010; Hawkes et al., 2010; Savica
et al., 2010; Schapira and Tolosa, 2010). Among these, demen-
tia is a particularly important aspect, since it brings an additional
and important burden of functional impairment associated with
signiﬁcant cognitive deterioration and further loss of QOL. The
achievements in the last few decades regarding cognitive and
behavioral issues in PD have been important scientiﬁc progresses
(Weintraub and Burn, 2011), but research on clinical management
is still scarce, particularly concerning randomized trials. There are
no known disease modifying strategies in PD-D and every therapy
here mentioned is currently seen as purely symptomatic.
Treating physicians should encourage an open dialog with the
patient and family regarding the issue of cognitive decline in PD,
especially when symptoms are brought to light by the patient or
the caregivers, or uncovered by the clinician. Subjective cogni-
tive complains should be noted and delved in detail. Functional
impairment due to cognitive deterioration should be searched
for in the several daily life environments, such as at home or at
work, by questioning the patient and signiﬁcant others. Sensi-
tive and user friendly screening scales like the Montreal Cognitive
Assessment (MoCA; Dalrymple-Alford et al., 2010) can be used to
quickly probe the severity of cognitive decline, although compre-
hensive neuropsychological assessment is the best way of deﬁning
the proﬁle of impairment in detail. Associated neuropsychiatric
symptoms should be searched for, so that they can be properly
addressed.
Common sense advises that, as in other circumstances
when cognitive decline is apparent, with or without concomi-
tant functional impairment (i.e., dementia), treatable causes
should be ruled out through suitable laboratory testing, such as
hypothyroidism, vitamin B12 or folate deﬁciencies, renal, or liver
failure, anemia, and exceptionally even VDRL or HIV antibodies
in the appropriate setting (i.e., classical risk factors). Structural
brain imaging should be considered in the context of new onset
cognitive decline, including when brain vascular disease or atyp-
ical degenerative parkinsonian disorders are suspected; magnetic
resonance imaging would be the modality of choice in this regard
(Bohnen and Albin, 2011; Wattjes, 2011). Exceptionally, genetic
testing canbe considered, in carefully selected circumstances above
mentioned in the text.
Marked cholinergic deﬁcits can be found in the brain of PD-D
patients (Kehagia et al., 2010), thus providing the rational basis
for cholinesterase inhibitor therapy in this condition. Only one
large randomized placebo-controlled trial has been published so
far regarding the use of cholinesterase inhibitors in PD-D (Emre
et al., 2004). Emre and collaborators have demonstrated that
rivastigmine, a dual inhibitor of acetylcholinesterase and butyryl-
cholinesterase, brings modest but signiﬁcant improvements in
mild to moderate PD-D. As expected, gastrointestinal adverse
events such as nausea and vomiting were more common in the
group treated with rivastigmine. One wonders whether newer for-
mulations (i.e., transdermal patch) would reduce gastrointestinal
adverse events as compared to capsules, which has already been
demonstrated for AD in the large randomized, controlled, double-
blind, double-dummy IDEAL trial (Winblad et al., 2007). Interest-
ingly, visual hallucinations seem topredict better clinical outcomes
under rivastigmine, as a mean statistically signiﬁcant difference of
2.3 points on the Progressive Deterioration Scale has been docu-
mented in rivastigmine- versus placebo-treated patients without
hallucinations at baseline, compared with a mean statistically sig-
niﬁcant difference of 5.3 points in patients with hallucinations at
baseline (Emre et al., 2007b). Memantine has also been studied in
PD-D, with two randomized double-blind placebo-controlled tri-
als published thus far. One trial demonstrated marginal efﬁcacy of
memantine over placebo, regarding global clinical impression, and
attention, whereas it failed to establish signiﬁcant improvements
in other secondary outcome measures (Aarsland et al., 2009). The
second trial has shown clinical beneﬁts of memantine on global
clinical status and behavioral symptoms, but activities of daily liv-
ing and caregiver burden did not improve (Emre et al., 2010). Both
trials enrolled a mixed population of PD-D and DLB patients.
Behavioral or neuropsychiatric symptoms are common in PD-
D and often exceedingly disturbing for the patient and caregivers.
They must be properly explored and managed. Thorough ques-
tioning of both the patient and caregiver is paramount in this
regard. For instance, visual hallucinations are commonly uncov-
ered in clinic during patient interview, which were previously not
suspected at all by the astonished family.
No randomized controlled trials have been conducted regard-
ing the treatment of depression in PD-D. Tricyclic antidepressants
have been found superior to placebo in PD (Devos et al., 2008;
Menza et al., 2009), but their anticholinergic effects advises against
their use in PD-D, since the risk of additional cognitive deterio-
ration and new onset confusion would be signiﬁcantly increased
(Labbate et al., 2009). Thus, depression in PD-D is usually treated
with serotonin selective reuptake inhibitors (SSRIs), such as ser-
traline and citalopram, although evidence in favor of this practice
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is scarce (Wermuth et al., 1998; Leentjens et al., 2003; Weintraub
et al., 2006; Devos et al., 2008). Noradrenaline and serotonin reup-
take inhibitors like venlafaxine could be an alternative, but no
trials have been published so far in this setting. Nonetheless, clin-
ical practice has brought an overall positive experience with these
drugs. Bupropion, that inhibits the reuptake of dopamine and
noradrenaline, has been suggested by some to have a role in the
treatment of depression in PD (Raskin and Durst, 2010; Zaluska
and Dyduch, 2011), but controlled trials are also lacking. In any
case, it appears that sedation and sexual dysfunction are lowerwith
bupropion,when compared to SSRIs (Labbate et al., 2009). Recent
research has found that pramipexole, a dopamine agonist widely
used in the treatment of PD motor symptoms, improves depres-
sive symptoms in PD (Barone et al., 2010), but the prescription
should be carefully considered in PD-D due to the risk of visual
hallucinations and confusion with this drug class.
Psychotic symptoms can be a challenging clinical problem
in PD-D. Patients should be questioned about the content of
their visual hallucinations and whether these are disturbing or
not. They can be a source of signiﬁcant anxiety and agitation
or, on the other hand, be felt by the patient as friendly or at
least non-threatening. At times the diagnosis of delirium is con-
sidered in PD-D, as patients may appear confuse and attention
may become more volatile than usual. In this case, comorbid
medical conditions should be searched for and treated, such
as urinary tract infections, pneumonia, gastroenteritis, dehydra-
tion, or aggravated pre-existent disorders (e.g., renal or cardiac
failure). Certain drugs seem prone to cause psychosis and con-
fusional states, thus pharmacological therapy should be thor-
oughly reviewed and optimized. Antiparkinsonian drugs are often
implicated – anticholinergics, selegiline, amantadine, dopamine
agonists, and catechol-O-methyltransferase inhibitors should be
discontinued, and lastly, a reduction in levodopa dosage should
be considered. However, this approach is also not evidence-based.
Antipsychotics should be used only as a last resort in PD-D. Atyp-
ical agents such as quetiapine can be used, despite the fact that
trial results do not support this strategy (Ondo et al., 2005; Rabey
et al., 2007; Shotbolt et al., 2009). Clozapine has been studied with
a few positive results in PD patients (The Parkinson Study Group,
1999; Fernandez et al., 2004), but the hematological safety proﬁle
and signiﬁcant muscarinic receptor afﬁnity (Bymaster et al., 2003;
Gareri et al., 2008) advise against its use in PD-D. Ondansetron, a
5-HT3 receptor antagonist used for the treatment of severe vom-
iting, especially in the setting of cancer chemotherapy, has also
been tried as an antipsychotic agent, based on the rational that
psychotic symptoms could be due to central serotoninergic over-
stimulation; Zoldan and coworkers conducted an open-label trial
for 4–8weeks, enrolling 16 PD patients with psychosis (daily dose
12–24mg). They have found that psychotic symptoms were sig-
niﬁcantly improved, with good tolerability and no repercussion
on PD motor symptoms, levodopa efﬁcacy, or general cognitive
state (Zoldan et al., 1995). However, this line of research has not
been followed subsequently by any other group, probably due to
the high cost of the drug. Coping strategies to deal with hallucina-
tions might be helpful for patients and caregivers (Diederich et al.,
2009).
CONCLUSION
Parkinson’s disease is much more than a motor disorder and a
wide range of non-motor symptoms have been recognized along
the years, especially in the last decades. Among them, cognitive
decline, in a wide range of severity, is particularly important to
recognize, due to the meaningful impact on the life of patients
and caregivers, as well as the social and economic burden brought
about by this condition. Expert consensus guidelines have been
recently issued speciﬁcally for the diagnosis of MCI in PD and PD
dementia. These have not been prospectively assessed so far, but
might prove useful both in clinical and research settings, as clin-
ical decisions and research methods will hopefully become more
homogeneous.An array of cognitive and behavioral symptoms has
been associated with PD-D, which should be properly character-
ized and managed, as patients beneﬁt from speciﬁc interventions.
Nevertheless, many clinical decisions and practices do not ﬁnd
solid support on evidence-baseddata, and rely on the older and less
objective“experience-based medicine”practices. This is an impor-
tant point to be addressed in the future, asmulticenter randomized
trials using recent consensus deﬁnitions should be considered in
relevant clinical areas.
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